Last reviewed · How we verify
Tucatinib (ONT-380) (tucatinib-ont-380)
At a glance
| Generic name | tucatinib-ont-380 |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Approved indications
Common side effects
- Diarrhoea
- Nausea
- Fatigue
- Palmar-plantar erythrodysaesthesia syndrome
- Vomiting
- Decreased appetite
- Headache
- Constipation
- Stomatitis
- Anaemia
- Arthralgia
- Aspartate aminotransferase increased
Key clinical trials
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer (PHASE1, PHASE2)
- A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (PHASE2)
- A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors (PHASE2)
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (PHASE3)
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (PHASE3)
- Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer (PHASE2)
- A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) (PHASE2)
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |